Advancing clinical development of gout drug Bucillamine for infectious diseases, including COVID-19
Developing novel psilocybin and cannabidiol therapeutics for central nervous system and inflammatory disorders
Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) is a life sciences company focused on the research and development of drugs for infectious diseases as well as central nervous system and inflammatory disorders.
Its cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. The company has been granted orphan drug status designation by the US Food and Drug Administration (FDA) for the use of CBD to treat auto-immune hepatitis and FDA orphan drug status designation for the use of CBD to treat ischemia and reperfusion injury from organ transplantations.
NHRI finding could curb spread of prostate cancer
Staff writer, with CNA
National Health Research Institutes (NHRI) researchers have found that stimulating activity of a certain gene might suppress the ability of prostate cancer to spread to the bones, a finding they said could lead to new medicines.
Chuu Chih-pin (褚志斌), an associate researcher at the NHRI’s Institute of Cellular and System Medicine, said in a statement on Friday that the team’s research focused on the role of the ROR2 gene, which is involved in the chemical signaling that regulates cellular activity.
Prostate cancer is the second-most common cancer among men globally and the sixth-most common cancer in Taiwan, Chuu said.
Taiwan researchers find a key to prostate cancer metastasis
04/16/2021 08:51 PM
NHRI associate researcher Chuu Chih-pin. Photo courtesy of the NHRI
Taipei, April 16 (CNA) Researchers at Taiwan s National Health Research Institutes (NHRI) have found that stimulating activity in a certain gene may suppress the ability of prostate cancer to spread to the bones, a finding they said could lead to new medicines.
Chuu Chih-pin (褚志斌), an associate researcher at the NHRI s Institute of Cellular and System Medicine, said in a statement Friday that the team s research focused on the role of the ROR2 gene, which is involved in chemical signaling that regulates cellular activity. In the statement, Chuu explained that prostate cancer is the second-most common cancer in men worldwide and the sixth-most common cancer overall in Taiwan.
Article content
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical company, is pleased to provide an update on its psychedelic product programs as it relates to the clinical and commercial development of ketamine and the research and development of proprietary microneedle patch delivery systems for psychedelics such as ketamine, psilocybin, N,N-Dimethyltryptamine (“DMT”), 3,4-Methylenedioxymethamphetamine (“MDMA”) and lysergic acid diethylamide (“LSD”).
“Over the last 12 months, we have been focused on building our intellectual property portfolio, which currently consists of 17 granted patent and patent applications, advancing the clinical development of our ketamine product pipeline targeting Parkinson’s disease, depression and Lou Gehrig’s disease, and developing novel microneedle patch delivery systems to unlock the clinical value of
Share this article
Share this article
PALM BEACH, Fla., April 14, 2021 /PRNewswire/ The psychedelics industry may appear to have suddenly emerged as one of the hottest corners of the stock market, but researchers have been working for decades to show the efficacy of these treatments and regulators are just starting to appreciate the possibilities. Investors could see strong growth in the industry as companies commercialize breakthrough therapeutics while patients could finally have access to life-changing treatments for a range of mental health conditions that have no effective treatment options today. A recent article by CFN Media Group focused on the newly born psychedelics industry in terms of both its revenue potential and the valuations that investors are assigning to companies in the space. Another article said: The market for psychedelic drugs is projected to grow from just over $2 billion last year to about $6.9 billion by 2027, according to Data Bridge Market Resear